Physician profile
Robert D Bohnert
NPI 1174293559
$3,503.03
in general payments reported to CMS, 2019-2025
39 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.24 · 2022: $454 · 2023: $590 · 2024: $830 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.46 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.35 | 2023-2025 | Entyvio, Eohilia, Trintellix |
| Lilly USA, LLC | $333.98 | 2022-2025 | Mounjaro, Trulicity, Omvoh |
| Amgen INC. | $282.94 | 2022-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $254.81 | 2022-2025 | |
| Janssen Biotech, INC. | $166.68 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $108.26 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.96 | 2025 | Xifaxan |
| Genzyme Corporation | $94.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.29 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $88.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $85.09 | 2022-2024 | Strensiq |
| Madrigal Pharmaceuticals | $73.98 | 2025 | Rezdiffra |
| Novo Nordisk INC | $67.52 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.37 | 2024 | Jardiance, Tradjenta, Synjardy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bohnert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.